DNA Methylation and Autoimmune Thyroid Diseases
DNA Methylation and Autoimmune Thyroid Diseases
Hashimoto Thyroiditis (HT) and Graves Disease (GD) are known to be caused by abnormal immune
 response against self cells and tissues. Epigenetics is a novel field of biology studying the
 mechanisms by which the environment interacts with the genotype to produce a variety of
 phenotypes through modifications to chromatin that do not directly alter the DNA sequence. A
 very limited number of epigenetic studies have been published in patients with HT and GD so
 far. Therefore, the purpose of this study is to analyze DNA methylation status in White Blood
 Cells (WBCs) within the promoter regions of genomic sites that have been previously
 identified as susceptibility loci or sites for autoimmune thyroid disease, such as the CD40L,
 FOXP3, CTLA4, PTPN22, IL2RA, FCRL3 and HLADRB1 genes.
Hashimoto Thyroiditis (HT) and Graves Disease (GD) are known to be caused by abnormal immune
 response against self cells and tissues. HT involves a cell-mediated autoimmune destruction
 of the thyroid leading to hypothyroidism. GD is caused by a process in which immune cells
 make stimulating antibodies against the thyroid stimulating hormone (TSH) receptor on the
 thyroid gland, thus leading to hyperthyroidism. Although there is substantial evidence that
 genetic factors increase the risk for developing autoimmune diseases, monozygotic twins still
 remain discordant for disease (disease concordance is never 100%), thus suggesting a role for
 environmental factors and epigenetics.

 Epigenetics is a novel field of biology studying the mechanisms by which the environment
 interacts with the genotype to produce a variety of phenotypes through modifications to
 chromatin that do not directly alter the DNA sequence. These modifications have been
 associated with altered gene expression and silencing of repetitive elements and can be
 inherited mitotically. Epigenetic mechanisms include DNA methylation, histone modifications,
 or miRNA post-transcriptional regulation. DNA methylation involves the covalent addition of a
 methyl group to the carbon-5 position in the CpG dinucleotide from the methyl donor
 S-adenosylmethionine and is mediated by a group of enzymes called DNA methyltransferases
 (DNMTs). CpG dinucleotides are typically grouped together in regions known as CGIs (islands).
 CGIs can be found in the promoter regions of genes, and CpG methylation of these gene
 promoters is associated with transcriptional silencing. In contrast, hypermethylated genes
 have been found to be transcriptionally active.

 A very limited number of epigenetic studies have been published in patients with HT and GD so
 far. Therefore, the purpose of this study is to analyze DNA methylation status in White Blood
 Cells (WBCs) within the promoter regions of genomic sites that have been previously
 identified as susceptibility loci or sites for autoimmune thyroid disease, such as the CD40L,
 FOXP3, CTLA4, PTPN22, IL2RA, FCRL3 and HLADRB1 genes.

 Initially, recruitment of patients and controls as well as blood sample collection will be
 done. A complete physical examination will also be performed in all participants included in
 the study, and a detailed personal, family, gestational and perinatal history will be
 obtained as well before inclusion. Blood samples by all participants will be collected and
 centrifuged and then White Blood Cells (WBCs), plasma and serum will be separated and stored
 in a deep freezer.

 Laboratory analyses will follow. DNA will be isolated from peripheral leukocytes using the
 QIAamp DNA Blood Mini Kit, according to the manufacturer's instructions. It will then be
 treated with sodium bisulfite using the Zymo EZ DNA Methylation-Gold Kit, again according to
 the manufacturer's protocol. Therefore, unmethylated cytosines will be converted into
 uracyls, whereas methylated cytosines will remain unchanged. Quantification of the
 methylation status of DNA at the gene promoter regions under study will be made, using
 specific primers that detect modified DNA, by real-time PCR and analysis of the melting
 curves of the selected fragments of DNA. Amplicons will also be analyzed by electrophoresis
 and visualized by ultraviolet trans-illumination.

 An electronic Data Base will be constructed and Statistical Analysis will follow. Results and
 Conclusions will be published in peer-review journals and presented in International
 Meetings.
Inclusion Criteria:

 For HT:

 A positive titers of antithyroid peroxidase (anti-TPO) or antithyroglobulin (anti-Tg)
 antibodies and at least one of:

 -  Abnormal thyroid function that requires substitution treatment with L-thyroxine (TSH >
 5 μIU/ml and decreased or normal levels of fT4 or fT3)

 -  Increased volume of thyroid gland (goiter)

 -  Morphological changes on ultrasound of the thyroid gland

 For GD:

 -  A positive titers of thyroid stimulating antibodies (anti-TSI) and

 -  Decreased TSH levels and increased levels of fT4 or fT3

 For Controls:

 -  Otherwise healthy children and adolescents, age- and gender-matched with patients

 -  Absence of previously known chronic disease of autoimmune aetiology or atopy
 (including those with a history of chronic treatment with antihistamines,
 anti-inflammatory, corticosteroids or anti-epileptic drugs)

 -  Absence of a family history of autoimmune disease in first-degree relatives

 Exclusion Criteria:

 -  Not Caucasian origin or affinity among participants

 -  Age of diagnosis above 18 years

 -  Disease duration below 3 months